Prostacyclin for pulmonary arterial hypertension - Barnes, H - 2019 | Cochrane Library https://t.co/eI6QwGNrTG

RT @CochraneAirways: Congratulations to @hayleynbarnes and team at @AlfredHealth @APHP @MonashUni on the publication of Cochrane Systematic…

RT @CochraneAirways: Congratulations to @hayleynbarnes and team at @AlfredHealth @APHP @MonashUni on the publication of Cochrane Systematic…

Congratulations to @hayleynbarnes and team at @AlfredHealth @APHP @MonashUni on the publication of Cochrane Systematic review on Prostacyclin for pulmonary arterial hypertension https://t.co/H2ws19zuOm

Have u always wondered what the evidence is for the different preparations of prostacyclin in PAH? See our comprehensive Cochrane review to find out! https://t.co/IVmWjXXv5c

RT @CochraneAirways: New #CochraneEvidence: Prostacyclin for pulmonary arterial hypertension https://t.co/H2ws19zuOm

The effect of oral prostacyclins are less certain. Selexipag demonstrated less clinical worsening without discernible impact on survival, increased adverse events; and the effect on other outcomes is less certain [5/5] https://t.co/H2ws19zuOm

Review included 17 trials with 3765 mostly adult participants. Median trial duration was 12 weeks. https://t.co/H2ws19zuOm [1/5]

New #CochraneEvidence: Prostacyclin for pulmonary arterial hypertension https://t.co/H2ws19zuOm